Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

26 November 2020
Pharma

Precision Cancer Diagnostic Test Market Report 2021-2031: Forecasts by Category (Cancer Imaging, Molecular Cancer Testing, Tumour Marker Immunoassays, POC Colon Cancer Tests), by Cancer Imaging Test (Computed Tomography, Magnetic Resonance Imaging, Digital & Analog Mammography, Positron Emission Tomography, Digital Breast Tomosynthesis, Molecular Breast Imaging), by Molecular Cancer Testing (Blood-Based Molecular Cancer Tests, HPV Genotyping, Circulating Tumour Cell (CTC) Tests, Next-Generation Sequencing Tests), by End-user (Hospitals, Clinics, Research Institutes) and Regional and Leading National Market Analysis PLUS Analysis of Leading Precision Cancer Diagnostic Test Companies AND COVID-19 Recovery Scenarios.

Are you curious to know Why Precision Cancer Diagnostics Test Markets is growing and how it could benefit you?
Advanced diagnostics for cancer represent a major market opportunity for life sciences companies. Many cancer types are on the rise as the aging populations of many countries continue to grow. As a result, there is an increasing demand for non-invasive, diagnostic assays that can detect cancers earlier, molecularly subtype tumours to guide therapy decisions and monitor cancer recurrence in treated individuals. According to Visiongain analysis, the global precision cancer diagnostic test market is estimated to be valued at US$xx million in 2020 and is projected to reach at a market value of US$xx million by 2031.

Are significant new product launches propelling the market growth?
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers. New molecular diagnostics can simplify decision-making and reduce uncertainty, but can also complicate treatment selection: multiple tests may be used to identify markers, and their results are likely to vary in specificity and sensitivity. Molecular diagnostics are rapidly transforming drug development and patient selection.

Buy this report to find answers for below questions and how can help you to stay updated
• How much will the precision cancer diagnostic tests industry share grow during the forecast timeline?
• Are Political influence and online misinformation threatening cancer programmes worldwide?
• Is it true that public trust volatile and varying widely between countries?
• How scepticism about the safety of cancer diagnostic test tend to hamper precision cancer diagnostic test Sales Growth?
• Perceptions about cancer diagnostic test are much more volatile than they used to be?
• Are governments Planning to be extra vigilant about assessing public trust in cancer diagnostic test and responding rapidly to concerns?
• Consumers are more keen on thoroughness, effectiveness and safety of precision cancer diagnostic tests than other factors
• How are precision cancer diagnostic tests at diagnostic centres better than that done at hospitals?

Leading Players Profiled in the Report
Abbott Laboratories
Agilent Technologies, Inc.
Becton, Dickinson and Company (BD)
Bio-Rad Laboratories, Inc.
Canon Inc.
Biocept, Inc.
Danaher Corporation (Danaher)
Roche Holding AG (Roche)
ANGLE plc
Epigenomics AG
General Electric Company
Siemens AG
Biomerieux SA
Hologic, Inc.
Myriad Genetics, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever